Cogent Biosciences terminates $75M ATM equity offering agreement with SVB Securities

Cogent Biosciences, Inc.

Terminated Sales Agreement with SVB Securities LLC (f/k/a SVB Leerink) for an at-the-market offering program.
The ATM allowed the company to sell up to $75 million of common stock at its sole discretion.
Termination effective May 5, 2022; the facility is no longer available for use.
Original agreement was entered into on February 8, 2021 and filed as Exhibit 1.2 to the S-3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.